Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Tennessee WIN TennCare Expands Coverage for Obesity Medications Obesity Action Coalition applauds TennCares (Tennessee Medicaid) decision to cover obesity medications effective August 1, 2025 for beneficiaries 21 years or older
Interleukin-16 enhances anti-tumor immune responses by Establishing a Th1 cell-macrophage crosstalk through reprogramming glutamine metabolism in mice
Xiao X, Moschetta GA, Xu Y, Fisher AL, Alfaro-Magallanes VM, Dev S, et al
Novo Nordisk said the outlook for its International Operations business reflects continued volume penetration from GLP-1 treatments and market expansion, mainly within obesity, as well as intensifying competition and negative impacts from the compound patent expiry of the semaglutide molecule in certain markets. International Operations sales increased 6% at constant exchange rates during the first quarter, driven by growth in Europe and Asia-Pacific markets, although the company said the performance was partly offset by weakness in emerging markets and China
US$ 25.83
US$ 23.38
US$ 22.70
US$ 25.90
US$ 22.46
